2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
13
Motor Activity
5
Colorectal Neoplasms
5
Smoking Cessation
4
Neoplasms
4
Lung Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Smoking
2
Prostatic Neoplasms
2
Papillomavirus Infections
2
Colonic Neoplasms
2
Behavior
2
Skin Cancer Prevention
1
Polycystic Ovary Syndrome
1
Patient Compliance
1
Pancreatic Neoplasms
1
Overweight
1
Ovarian Neoplasms
1
Other Cancer
1
Obesity
1
Melanoma
1
Medication Adherence
1
Lymphedema
1
Gastrointestinal Neoplasms
1
Colorectal Cancer Screening
1
Chronic Pain
1
Body Weight Changes
1
Body Weight
1
Anxiety Disorders
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
135
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
67
fludarabine phosphate
61
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Cisplatin
36
CTLA-4 Antigen
36
Carboplatin
35
cobimetinib
34
Specimen Handling
34
Magnetic Resonance Spectroscopy
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Motivational Interviewing
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled